Do analysts prefer CUE or AGMB?

AgomAb Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 158.28%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has preferable valuation & earnings, CUE or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cue Biopharma $27.47M 3.98 -$26.60M -$5.58 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Do analysts rate INDP or CUE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CUE or EOLS?

Evolus has a consensus price target of $16.00, indicating a potential upside of 129.26%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is CUE or EOLS more profitable?

Evolus has a net margin of -14.39% compared to Cue Biopharma's net margin of -59.65%. Evolus' return on equity of 0.00% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -59.65% -98.30% -53.69% Evolus -14.39% N/A -19.03%

Do analysts prefer CUE or AUTL?

Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 445.17%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Cue Biopharma (CUE) Competitors

$26.01 -0.89 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$26.58 +0.56 (+2.17%)

As of 05:38 PM Eastern

Compare

CUE vs. AGMB, INDP, EOLS, AUTL, and IPSC

Should you buy Cue Biopharma stock or one of its competitors? MarketBeat compares Cue Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cue Biopharma include AgomAb Therapeutics (AGMB), Indaptus Therapeutics (INDP), Evolus (EOLS), Autolus Therapeutics (AUTL), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry.

How does Cue Biopharma compare to AgomAb Therapeutics?

Cue Biopharma (NASDAQ:CUE) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

AgomAb Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. AgomAb Therapeutics' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
AgomAb Therapeutics	N/A	N/A	N/A

In the previous week, AgomAb Therapeutics had 13 more articles in the media than Cue Biopharma. MarketBeat recorded 13 mentions for AgomAb Therapeutics and 0 mentions for Cue Biopharma. AgomAb Therapeutics' average media sentiment score of 0.25 beat Cue Biopharma's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Neutral
AgomAb Therapeutics	Neutral

AgomAb Therapeutics has lower revenue, but higher earnings than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

AgomAb Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 158.28%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

35.0% of Cue Biopharma shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AgomAb Therapeutics beats Cue Biopharma on 8 of the 11 factors compared between the two stocks.

How does Cue Biopharma compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Cue Biopharma	-59.65%	-98.30%	-53.69%

In the previous week, Indaptus Therapeutics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 0 mentions for Cue Biopharma. Indaptus Therapeutics' average media sentiment score of 0.46 beat Cue Biopharma's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Cue Biopharma	Neutral

Indaptus Therapeutics has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

Summary

Indaptus Therapeutics and Cue Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Cue Biopharma compare to Evolus?

Cue Biopharma (NASDAQ:CUE) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Evolus has a consensus price target of $16.00, indicating a potential upside of 129.26%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cue Biopharma has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A
Evolus	$297.18M	1.55	-$51.64M	-$0.67	N/A

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cue Biopharma has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Evolus has a net margin of -14.39% compared to Cue Biopharma's net margin of -59.65%. Evolus' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Evolus	-14.39%	N/A	-19.03%

In the previous week, Evolus had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Evolus and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.00 equaled Evolus'average media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Neutral
Evolus	Neutral

Summary

Evolus beats Cue Biopharma on 10 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Autolus Therapeutics?

Cue Biopharma (NASDAQ:CUE) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Cue Biopharma has a net margin of -59.65% compared to Autolus Therapeutics' net margin of -311.98%. Cue Biopharma's return on equity of -98.30% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Autolus Therapeutics' average media sentiment score of 0.06 beat Cue Biopharma's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Neutral
Autolus Therapeutics	Neutral

Cue Biopharma has higher earnings, but lower revenue than Autolus Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A
Autolus Therapeutics	$75.39M	5.67	-$287.53M	-$1.09	N/A

Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 445.17%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Cue Biopharma has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

Autolus Therapeutics beats Cue Biopharma on 12 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Century Therapeutics currently has a consensus price target of $4.75, indicating a potential upside of 107.42%. Given Century Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Century Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Century Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Century Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Century Therapeutics' return on equity of -49.89% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Cue Biopharma	-59.65%	-98.30%	-53.69%

In the previous week, Century Therapeutics' average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Century Therapeutics	Neutral
Cue Biopharma	Neutral

Century Therapeutics has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.78	-$9.58M	-$1.14	N/A
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Century Therapeutics beats Cue Biopharma on 11 of the 14 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$112.99M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.66	20.50	25.39	23.96
Price / Sales	3.98	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.58	8.26	10.76	6.41
Net Income	-$26.60M	$23.91M	$3.56B	$337.14M
7 Day Performance	-2.69%	3.05%	1.37%	-0.48%
1 Month Performance	21.15%	2.40%	0.81%	0.49%
1 Year Performance	-96.00%	56.35%	30.53%	28.16%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.087 of 5 stars	$26.01 -3.3%	N/A	-95.3%	$112.99M	$27.47M	N/A	60
AGMB AgomAb Therapeutics	N/A	$12.30 +3.9%	$32.75 +166.3%	N/A	$445.68M	N/A	N/A	62	Trending News Analyst Forecast Analyst Revision Gap Up
INDP Indaptus Therapeutics	1.1219 of 5 stars	$3.91 +3.4%	N/A	-73.5%	$442.77M	N/A	N/A	6	News Coverage Positive News
EOLS Evolus	1.8954 of 5 stars	$6.70 +1.6%	$16.00 +139.0%	-28.1%	$440.90M	$301.79M	N/A	170
AUTL Autolus Therapeutics	3.6398 of 5 stars	$1.63 +9.5%	$8.75 +436.5%	-24.9%	$435.17M	$92.62M	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. AGMB, INDP, EOLS, AUTL, and IPSC

How does Cue Biopharma compare to AgomAb Therapeutics?

Summary

How does Cue Biopharma compare to Indaptus Therapeutics?

Summary

How does Cue Biopharma compare to Evolus?

Summary

How does Cue Biopharma compare to Autolus Therapeutics?

Summary

How does Cue Biopharma compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. AGMB, INDP, EOLS, AUTL, and IPSC

How does Cue Biopharma compare to AgomAb Therapeutics?

Is CUE or AGMB more profitable?

Does the media favor CUE or AGMB?

Which has preferable valuation & earnings, CUE or AGMB?

Do analysts prefer CUE or AGMB?

Do insiders & institutionals hold more shares of CUE or AGMB?

Summary

How does Cue Biopharma compare to Indaptus Therapeutics?

Do analysts rate INDP or CUE?

Is INDP or CUE more profitable?

Does the media favor INDP or CUE?

Which has better earnings & valuation, INDP or CUE?

Do institutionals and insiders hold more shares of INDP or CUE?

Which has more risk and volatility, INDP or CUE?

Summary

How does Cue Biopharma compare to Evolus?

Do analysts rate CUE or EOLS?

Which has stronger earnings and valuation, CUE or EOLS?

Do institutionals & insiders believe in CUE or EOLS?

Which has more volatility and risk, CUE or EOLS?

Is CUE or EOLS more profitable?

Does the media refer more to CUE or EOLS?

Summary

How does Cue Biopharma compare to Autolus Therapeutics?

Is CUE or AUTL more profitable?

Do insiders & institutionals have more ownership in CUE or AUTL?

Does the media refer more to CUE or AUTL?

Which has preferable earnings and valuation, CUE or AUTL?

Do analysts prefer CUE or AUTL?

Which has more risk and volatility, CUE or AUTL?

Summary

How does Cue Biopharma compare to Century Therapeutics?

Do analysts prefer IPSC or CUE?

Which has more volatility & risk, IPSC or CUE?

Is IPSC or CUE more profitable?

Does the media favor IPSC or CUE?

Which has preferable valuation & earnings, IPSC or CUE?

Do insiders and institutionals hold more shares of IPSC or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools